NasdaqGM - Delayed Quote • USD
Cara Therapeutics, Inc. (CARA)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 6:29 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | -0.4 | -0.25 | -1.09 | -1.02 |
| Low Estimate | -0.43 | -0.26 | -1.23 | -1.34 |
| High Estimate | -0.35 | -0.23 | -0.84 | -0.68 |
| Year Ago EPS | -0.49 | -0.58 | -2.19 | -1.09 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | 1.69M | 1.44M | 5.59M | 3.67M |
| Low Estimate | 300k | 80k | 1.3M | -- |
| High Estimate | 3.02M | 3.54M | 13.66M | 12.55M |
| Year Ago Sales | 6.17M | 6.93M | 20.97M | 5.59M |
| Sales Growth (year/est) | -72.60% | -79.20% | -73.30% | -34.30% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.52 | -0.54 | -0.52 | -0.41 |
| EPS Actual | -0.49 | -0.58 | -0.52 | -0.59 |
| Difference | 0.03 | -0.04 | 0 | -0.18 |
| Surprise % | 5.80% | -7.40% | 0.00% | -43.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.4 | -0.25 | -1.09 | -1.02 |
| 7 Days Ago | -0.4 | -0.25 | -1.15 | -1.11 |
| 30 Days Ago | -0.4 | -0.25 | -1.15 | -1.11 |
| 60 Days Ago | -0.42 | -0.31 | -1.26 | -0.94 |
| 90 Days Ago | -0.46 | -0.42 | -1.99 | -1.36 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | 1 |
| Up Last 30 Days | 1 | 1 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CARA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 18.40% | -- | -- | 1.60% |
| Next Qtr. | 56.90% | -- | -- | 10.50% |
| Current Year | 50.20% | -- | -- | 5.20% |
| Next Year | 6.40% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 110.70% | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | Needham: Buy to Buy | 4/10/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 3/6/2024 |
| Reiterates | Needham: Buy to Buy | 3/5/2024 |
| Maintains | Needham: Buy to Buy | 1/22/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 12/19/2023 |
| Maintains | Needham: Buy to Buy | 12/18/2023 |
Related Tickers
TARA Protara Therapeutics, Inc.
2.6400
-4.00%
ADVM Adverum Biotechnologies, Inc.
11.34
+1.70%
APLT Applied Therapeutics, Inc.
4.3800
-7.59%
BCAB BioAtla, Inc.
2.1050
-13.37%
DSGN Design Therapeutics, Inc.
3.7000
-1.07%
KPTI Karyopharm Therapeutics Inc.
1.1700
-8.59%
RAPT RAPT Therapeutics, Inc.
7.95
+0.25%
IMUX Immunic, Inc.
1.1800
-7.09%
HOOK HOOKIPA Pharma Inc.
0.7330
-4.17%
VTYX Ventyx Biosciences, Inc.
4.4700
+2.76%